BMS receives offer from Taisho to purchase UPSA30 Dec 2018
The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.
Taisho Pharmaceutical Holdings has offered to purchase Bristol-Myers Squibb’s UPSA consumer health business for $1.6 billion.
UPSA develops and delivers important consumer medicines for patients in France, across Europe and additional countries. Taisho is the largest OTC drug company in Japan, with over a century of experience in this field. Taisho holds a leading presence in anti-inflammatory analgesic, cold and flu and hair growth segments in Japan and Southeast Asia. The potential transaction is anticipated to be completed during the first half of 2019, subject to regulatory approvals and satisfaction of certain other customary closing conditions.
“This announcement marks the culmination of an in-depth strategic review to identify the best option to grow the UPSA business for the long-term,” said Giovanni Caforio, chairman and chief executive officer of BMS. “UPSA is a strong business that deserves the best possible opportunities for its employees and its future development. With Taisho we have found an experienced and reliable buyer with the strategic interest to successfully sustain and grow the business for the future.”
BMS and Taisho have a history of conducting successful transactions. In 2009, Taisho entered the OTC market in certain Asian countries through the purchase of PT Squibb Indonesia from BMS. The subsidiary of Taisho is now known as PT Taisho Pharmaceuticals Indonesia Tbk.
UPSA is a French pharmaceutical company and brand owned by Bristol-Myers Squibb. Since 1935, UPSA has built its expertise in the development and manufacturing of pharmaceutical drugs and supplements for everyday ailments. Its portfolio covers a wide range of therapeutic areas: pain, cough & cold, vitamins and supplements, gastrointestinal and sleep.
Over the past several years, BMS has been realigning its business portfolio to address changes in its business and the future requirements of its evolving pipeline. The company is focusing resources on its highest priorities of discovering, developing and delivering transformational medicines for patients facing serious diseases. UPSA is focused on consumer medicines that are outside of the BMS core focus.
Allergan to establish R&D presence in Cambridge, Massachusetts
10 Jan 2019
The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.Read more
Expedeon signs supply and license agreement for is Lightning-Link technology
9 Jan 2019
The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.Read more
Lilly to bag Loxo Oncology for $8 billion
8 Jan 2019
Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.Read more
Catalent to double its commercial biomanufacturing capacity
7 Jan 2019
The $200-million expansion will support customers’ development programs and commercial launches.Read more
BMS and Celgene merge to create premier innovative biopharma company
3 Jan 2019
Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.Read more
Cambrex completes acquisition of Avista Pharma Solutions
2 Jan 2019
Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.Read more
Novartis offers to acquire CellforCure
1 Jan 2019
Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.Read more
Recipharm to potentially end operations in Ashton-under-Lyne facility
24 Dec 2018
The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.Read more
An increased risk of a hard or ‘no deal Brexit?
24 Dec 2018
A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.Read more
Alcon acquires Tear Film Innovations
20 Dec 2018
Tear Film's iLux Device offers innovative, customizable treatment for Meibomian Gland Dysfunction, a leading cause of dry eye.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation